| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Departments of Pediatrics, Anesthesiology, and Pharmacology, University of Washington School of Medicine, Seattle, Washington 98105-00371; 3 Pediatric Heart-Lung Center, Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado 80218; and 2 Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island 02903
An experimental ovine fetal model for perinatal pulmonary hypertension of the neonate (PPHN) was characterized by altered pulmonary vasoreactivity and structure. Because past studies had suggested impaired nitric oxide-cGMP cascade in this experimental model, we hypothesized that elevated phosphodiesterase (PDE) activity may contribute to altered vascular reactivity and structure in experimental PPHN. Therefore, we studied the effects of the PDE inhibitors zaprinast and dipyridamole on fetal pulmonary vascular resistance and PDE5 activity, protein, mRNA, and localization in normal and pulmonary hypertensive fetal lambs. Infusion of dipyridamole and zaprinast lowered pulmonary vascular resistance by 55 and 35%, respectively, in hypertensive animals. In comparison with control animals, lung cGMP PDE activity was elevated in hypertensive fetal lambs (150%). Increased PDE5 activity was not associated with either an increased PDE5 protein or mRNA level. Immunocytochemistry demonstrated that PDE5 was localized to vascular smooth muscle. We concluded that PDE5 activity was increased in experimental PPHN, possibly by posttranslational phosphorylation. We speculated that these increases in cGMP PDE activity contributed to altered pulmonary vasoreactivity in experimental perinatal pulmonary hypertension.
persistent pulmonary hypertension of the newborn; vasoregulation; dipyridamole; guanosine 3',5'-cyclic monophosphate
This article has been cited by other articles:
|
|
 |
|
  A. L. Firth and J. X. -J. Yuan Bringing down the ROS: a new therapeutic approach for PPHN Am J Physiol Lung Cell Mol Physiol, December 1, 2008; 295(6): L976 - L978. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Smolich, J. P. Mynard, and D. J. Penny Simultaneous pulmonary trunk and pulmonary arterial wave intensity analysis in fetal lambs: evidence for cyclical, midsystolic pulmonary vasoconstriction Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1554 - R1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Deruelle, T. R. Grover, and S. H. Abman Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L798 - L806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 105 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Larrue, S. Jaillard, M. Lorthioir, X. Roubliova, G. Butrous, T. Rakza, H. Warembourg, and L. Storme Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1193 - L1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Pauvert, S. Bonnet, E. Rousseau, R. Marthan, and J.-P. Savineau Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats Am J Physiol Lung Cell Mol Physiol, September 1, 2004; 287(3): L577 - L583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Thebaud, T. Petit, P. de Lagausie, J. Dall'Ava-Santucci, J.-C. Mercier, and A. T. Dinh-Xuan Altered Guanylyl-Cyclase Activity In Vitro of Pulmonary Arteries from Fetal Lambs with Congenital Diaphragmatic Hernia Am. J. Respir. Cell Mol. Biol., July 1, 2002; 27(1): 42 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Storme, T. A. Parker, J. P. Kinsella, R. L. Rairigh, and S. H. Abman Chronic hypertension impairs flow-induced vasodilation and augments the myogenic response in fetal lung Am J Physiol Lung Cell Mol Physiol, January 1, 2002; 282(1): L56 - L66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schutte, M. Witzenrath, K. Mayer, N. Weissmann, A. Schell, S. Rosseau, W. Seeger, and F. Grimminger The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L496 - L502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Thebaud, P. de Lagausie, D. Forgues, Y. Aigrain, J.-C. Mercier, and A. T. Dinh-Xuan ETA-receptor blockade and ETB-receptor stimulation in experimental congenital diaphragmatic hernia Am J Physiol Lung Cell Mol Physiol, May 1, 2000; 278(5): L923 - L932. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
